Skip to main content

Allison Casey

FDA Approval
02/14/2025
On February 14, 2025, the US Food and Drug Administration approved vimseltinib for patients with symptomatic tenosynovial giant cell tumor not amenable to surgical resection.
On February 14, 2025, the US Food and Drug Administration approved vimseltinib for patients with symptomatic tenosynovial giant cell tumor not amenable to surgical resection.
On February 14, 2025, the US...
02/14/2025
Oncology
Conference Coverage
02/13/2025
According to results from the TALAPRO-2 trial, the addition of talazoparib to enzalutamide significantly improved the overall survival among patients with homologous recombination repair-deficient castration-resistant prostate cancer in the...
According to results from the TALAPRO-2 trial, the addition of talazoparib to enzalutamide significantly improved the overall survival among patients with homologous recombination repair-deficient castration-resistant prostate cancer in the...
According to results from the...
02/13/2025
Oncology
Conference Coverage
02/13/2025
The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved the overall survival and several quality-of-life measures among patients with poor-risk, metastatic castration-resistant prostate cancer.
The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved the overall survival and several quality-of-life measures among patients with poor-risk, metastatic castration-resistant prostate cancer.
The addition of...
02/13/2025
Oncology
Conference Coverage
02/13/2025
According to the long-term data from the phase 3 CheckMate 9ER trial, nivolumab plus cabozantinib continued to show an efficacy benefit, compared with sunitinib among untreated patients with advanced renal cell carcinoma.
According to the long-term data from the phase 3 CheckMate 9ER trial, nivolumab plus cabozantinib continued to show an efficacy benefit, compared with sunitinib among untreated patients with advanced renal cell carcinoma.
According to the long-term data...
02/13/2025
Oncology
Conference Coverage
02/13/2025
According to results from the phase 1/2 ADAPT-BLADDER trial, durvalumab plus intravesical gemcitabine and docetaxel showed promising clinical efficacy with high response rates among patients with BCG-unresponsive non-muscle invasive bladder...
According to results from the phase 1/2 ADAPT-BLADDER trial, durvalumab plus intravesical gemcitabine and docetaxel showed promising clinical efficacy with high response rates among patients with BCG-unresponsive non-muscle invasive bladder...
According to results from the...
02/13/2025
Oncology
Conference Coverage
02/13/2025
According to a phase 2 study, cemiplimab plus standard-of-care chemotherapy demonstrated efficacy and safety among patients with locally advanced or metastatic penile carcinoma.
According to a phase 2 study, cemiplimab plus standard-of-care chemotherapy demonstrated efficacy and safety among patients with locally advanced or metastatic penile carcinoma.
According to a phase 2 study,...
02/13/2025
Oncology
Conference Coverage
02/13/2025
In the phase 3 COSMIC-313 trial, final results indicated that cabozantinib plus nivolumab and ipilimumab maintained its PFS benefit with comparable OS when compared with placebo plus nivolumab and ipilimumab among patients with intermediate...
In the phase 3 COSMIC-313 trial, final results indicated that cabozantinib plus nivolumab and ipilimumab maintained its PFS benefit with comparable OS when compared with placebo plus nivolumab and ipilimumab among patients with intermediate...
In the phase 3 COSMIC-313 trial,...
02/13/2025
Oncology
News
02/11/2025
A retrospective study compared outcomes among pediatric and adult patients with central nervous system tumors with NTRK gene fusion based on tumor histology and type of treatment.
A retrospective study compared outcomes among pediatric and adult patients with central nervous system tumors with NTRK gene fusion based on tumor histology and type of treatment.
A retrospective study compared...
02/11/2025
Oncology
News
02/11/2025
Despite a low absolute risk of thyroid cancer among patients receiving GLP-1RA therapy, there was an increased risk within the first year of GLP-1RA initiation when compared with 3 other diabetes drugs.
Despite a low absolute risk of thyroid cancer among patients receiving GLP-1RA therapy, there was an increased risk within the first year of GLP-1RA initiation when compared with 3 other diabetes drugs.
Despite a low absolute risk of...
02/11/2025
Oncology
Conference Coverage
01/28/2025
Data from the BESPOKE CRC study found ctDNA to be prognostic of DFS within the molecular residual disease and surveillance windows among patients with stage II to stage III colorectal cancer.
Data from the BESPOKE CRC study found ctDNA to be prognostic of DFS within the molecular residual disease and surveillance windows among patients with stage II to stage III colorectal cancer.
Data from the BESPOKE CRC study...
01/28/2025
Oncology